Ongoing Memory Disorders Trials
The following studies are ongoing, but are not currently enrolling new participants.
AHEAD Study
The AHEAD Study is the anti-amyloid antibody prevention treatment study for individuals at known risk for Alzheimer's disease. Researchers at the Alzheimer’s Disease and Memory Disorders Center (ADMDC) at Rhode Island Hospital are currently participating in a phase 3 clinical trial of an anti-amyloid antibody, BAN2401, for individuals who have normal memory, but have a known risk for developing Alzheimer’s disease, such as a family history of the disease. BAN2401 works by selectively targeting abnormal build-up of disease–associated amyloid beta in the brain.
The purpose of the AHEAD 3-45 study is to determine the safety and efficacy of BAN2401 in preventing Alzheimer’s disease. Only individuals with elevated levels of amyloid plaques in the brain as determined by a positron emission tomography (PET) scan will qualify to participate. In this study, participants will be randomly assigned to receive either BAN2401 or a placebo by intravenous infusion, one to two times per month. The AHEAD 3-45 study will last for about five years and is funded through a partnership with the US National Institutes on Aging, Eisai, and other organizations.
Clarity AD
This Phase 3 trial will test the effectiveness of the experimental drug BAN2401 as a possible treatment for Alzheimer's disease. BAN2401 is a monoclonal antibody that interferes with the formation of amyloid plaque, a hallmark of Alzheimer's. This 18-month study will test the effectiveness of the study drug in people with MCI or early Alzheimer's disease.